Report
FDA approves Rasonque, a first-in-class RAS inhibitor for pancreatic cancer
Nature Biotechnology reports that an early-stage trial also suggests the drug has promise in lung cancer.
TLDR
Nature Biotechnology reports that the FDA approved Rasonque, a first-in-class RAS inhibitor targeting the most common form of pancreatic cancer. It says an early-stage trial also showed promise in lung cancer.
Combined views
905
1 Source, first seen ago
2 likes1 saves1 reposts